The Efficacy and Safety of Valsartan in Obese and Non-Obese Pediatric Hypertensive Patients
Article first published online: 14 JUL 2011
© 2011 Wiley Periodicals, Inc.
The Journal of Clinical Hypertension
Volume 13, Issue 10, pages 758–766, October 2011
How to Cite
Meyers, K. E. C., Lieberman, K., Solar-Yohay, S., Han, G. and Shi, V. (2011), The Efficacy and Safety of Valsartan in Obese and Non-Obese Pediatric Hypertensive Patients. The Journal of Clinical Hypertension, 13: 758–766. doi: 10.1111/j.1751-7176.2011.00502.x
- Issue published online: 4 OCT 2011
- Article first published online: 14 JUL 2011
- Manuscript received: November 15, 2010; Revised: March 19, 2011; Accepted: March 22, 2011
J Clin Hypertens (Greenwich). 2011;13:758–766. ©2011 Wiley Periodicals, Inc.
This post hoc analysis assessed the efficacy and tolerability of valsartan for the treatment of hypertension in obese vs non-obese children and adolescents. After a 1-week antihypertensive washout period, 142 obese and 119 non-obese hypertensive children and adolescents aged 6 to 16 years were randomized to 2 weeks of once-daily treatment with valsartan 10 to 20 mg, 40 to 80 mg, or 80 to 160 mg, followed by re-randomization to either valsartan or placebo for an additional 2 weeks. Patients could continue to receive valsartan during an optional 52-week, open-label extension. Valsartan resulted in statistically significant (P<.05) and clinically relevant reductions in mean sitting blood pressure (BP), ranging from approximately 7/4 mm Hg (valsartan 10–20 mg) to 13/9 mm Hg (valsartan 80–160 mg) in both obese and non-obese patients. BP control was achieved in 44% of obese and 56% of non-obese patients. Following re-randomization, non-obese patients experienced an increase in BP during placebo treatment, albeit levels remained below baseline, whereas BP reductions were maintained in valsartan recipients (P<.05). The most frequent adverse events during the open-label phase were headache and fever. Valsartan provides similar antihypertensive efficacy in obese and non-obese hypertensive children and adolescents, with good tolerability in both patient populations.